EINSTEIN PE RIVAROXABAN PDF

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW. Published in , EINSTEIN-PE randomized 4, patients with acute PE to rivaroxaban or standard therapy with enoxaparin and a VKA. Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism ().

Author: Bragis Togami
Country: Bangladesh
Language: English (Spanish)
Genre: Relationship
Published (Last): 2 June 2014
Pages: 83
PDF File Size: 17.8 Mb
ePub File Size: 19.92 Mb
ISBN: 326-4-24268-795-3
Downloads: 12506
Price: Free* [*Free Regsitration Required]
Uploader: Gur

Like the others, it employed a noninferiority rather than a superiority design, and enrolled a relatively heterogeneous patient population. The principal safety outcome occurred in For example, the study’s noninferiority design einsteon have rendered ;e unable to detect small differences in relative efficacy between treatment arms.

The bleeding rates were similar in the two study groups, with fewer major bleeding events in the rivaroxaban group. It was also one of the first to employ an open-label design lacking matching placebos between groups. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Views Read View source View history.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

It differed from these studies in several notable ways, however. The rivaroxagan of a net clinical benefit occurred in 83 patients 3. To compensate for this, the study used a higher dose during the first 3 weeks of therapy 15mg BID followed by a lower maintenance dose 20mg daily.

P values are for noninferiority unless otherwise specified. The principal safety outcome was major or clinically relevant nonmajor bleeding. N Engl J Med. Some of these characteristics contribute to the study’s limitations. Among patients with acute PE, is rivaroxaban noninferior to warfarin in preventing recurrent VTE or bleeding? The bleeding rivaroxaan were similar in the two study groups, with fewer major bleeding events in the rivaroxaban group Close this section.

  GLAZUNOV CHANT DU MENESTREL PDF

The primary efficacy outcome was symptomatic recurrent venous thromboembolism. Rivaroxaban was noninferior to standard therapy noninferiority margin, 2.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Rates of other adverse events were similar in the two groups. Navigation menu Personal tools Create account Log in. The fixed dose regimen of rivaroxaban is at least as effective for the initial and long-term treatment of PE as the standard therapy with enoxaparin followed by a VKA Safety: Rev Clin Esp Barc.

In a randomized, open-label, event-driven, noninferiority trial involving patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg once daily with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. N Engl J Med ; Among patients with acute PE, rivaroxaban is noninferior to warfarin in preventing recurrent VTE, and is associated with similar bleeding rates.

Anticoagulation-trials: EINSTEIN-PE

ESC Guidelines on the diagnosis and management of acute pulmonary embolismadapted: Retrieved from ” http: A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, rivaroxabsn the need for laboratory monitoring.

In addition, its open-label design may have biased both patients and investigators. Comparisons are rivaroxaban vs.

Major bleeding was observed in 26 patients 1. At a mean follow-up of 7 months, rivaroxaban was noninferior to standard therapy in terms of the rate of recurrent symptomatic VTE 2. A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.

  COMMUNICATIELEER OOMKES PDF

The primary safety endpoint, a first major and clinically relevant non-major bleeding episode, was observed in This page was last modified on 3 Decemberat The trial’s generalizability is limited for pr reasons, including the fact that 1 patients were younger mean age 58 years than the general acute PE population and 2 the trial excluded patients with cancer. Despite these limitations, there remains a reasonably strong evidence base for rivaroxaban in acute VTE, which led to the FDA approval of rivaroxaban for these indications in November To compare rivaroxaban to standard anticoagulant therapy with enoxaparin and vitamin K antagonist VKA in the treatment of patients with acute ienstein PE.

Comment in N Engl J Med. Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism The New England Journal of Medicine.

Randomized, open-label phase III non-inferiority study Active treatment: Usable articles Hematology Pulmonology. Major bleeding occured in 1. This approach may also simplify the treatment of pulmonary embolism.

Recommend page Back to top.